We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biodynamics Plc | LSE:OBD | London | Ordinary Share | GB00BD5H8572 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.325 | 7,829,247 | 08:00:24 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.30 | 0.35 | 0.325 | 0.30 | 0.325 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 1.11M | -11.57M | -0.0065 | -0.49 | 5.82M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:26:39 | O | 34 | 0.30 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/5/2025 | 07:00 | UK RNS | Oxford BioDynamics PLC OBD’s Oxford Lab accredited by UKAS |
| 10/4/2025 | 16:10 | UK RNS | Oxford BioDynamics PLC Director/PDMR Shareholding |
| 02/4/2025 | 07:00 | UK RNS | Oxford BioDynamics PLC PDMR Dealing |
| 28/3/2025 | 10:35 | UK RNS | Oxford BioDynamics PLC Result of AGM |
| 17/3/2025 | 07:00 | UK RNS | Oxford BioDynamics PLC Board Changes |
| 14/3/2025 | 17:25 | UK RNS | Oxford BioDynamics PLC Holding(s) in Company |
| 13/3/2025 | 16:45 | ALNC |  Oxford BioDynamics expands UK insurance partnership with Bupa |
| 13/3/2025 | 07:00 | UK RNS | Oxford BioDynamics PLC Expansion of OBD/Bupa UK insurance partnership |
| 05/3/2025 | 16:00 | UK RNS | Oxford BioDynamics PLC Publication of 2024 Annual Report |
| 03/3/2025 | 07:00 | UK RNS | Oxford BioDynamics PLC PDMR Dealing / Grant of Share Options |
Oxford Biodynamics (OBD) Share Charts1 Year Oxford Biodynamics Chart |
|
1 Month Oxford Biodynamics Chart |
Intraday Oxford Biodynamics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/5/2025 | 08:50 | Oxford BioDynamics PLC | 1,735 |
| 13/3/2025 | 16:27 | OBD without the muppets | 335 |
| 15/1/2024 | 20:55 | OBD-23/03/21-110P-SP might go up exponentially given the potential in the US | 52 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 24/5/2025 09:20 by Oxford Biodynamics Daily Update Oxford Biodynamics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker OBD. The last closing price for Oxford Biodynamics was 0.33p.Oxford Biodynamics currently has 1,789,322,004 shares in issue. The market capitalisation of Oxford Biodynamics is £5,725,830. Oxford Biodynamics has a price to earnings ratio (PE ratio) of -0.49. This morning OBD shares opened at 0.33p |
Posted at 14/5/2025 07:41 by maverick247 5 reasons to add OBD to your watch list https://smallcappix. |
Posted at 13/3/2025 08:05 by kingston78 13 March 2025Oxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") Bupa UK insurance to cover Oxford BioDynamics' EpiSwitch® PSE prostate cancer test · Bupa UK insurance customers with a raised PSA level and no additional high risk factors or symptoms will now be covered for PSE, a smart blood test which accurately predicts the presence or absence of prostate cancer · Expansion of OBD/Bupa UK insurance partnership beyond existing coverage of CiRT significantly enhances access to PSE in the UK · Coverage for both OBD's PSE and CiRT3 tests reflects Bupa's commitment to leveraging advanced precision medicine testing to transform cancer care Oxford, UK - 13 March 2025 - Oxford BioDynamics Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, and Bupa announce an expanded strategic agreement to give its health insurance customers access to OBD's EpiSwitch PSE prostate cancer detection test. Bupa is a leading health insurer in the UK with around 3.9m customers. Robin Clark, Medical Director for Bupa Insurance, said: "We're pleased to partner with Oxford BioDynamics to cover the advanced EpiSwitch PSE test. The PSE provides a more accurate path to diagnosing prostate cancer, where getting an early diagnosis can make the disease nearly completely survivable. Offering the PSE and CiRT tests reflects our commitment to leverage the most advanced precision medicine testing to provide doctors with the tools they need to make informed decisions." Under this new agreement, the PSE test will be funded for Bupa health insurance customers with a raised prostate-specific antigen level and no additional high-risk factors or urinary symptoms. The EpiSwitch PSE is OBD's validated, rapid, highly accurate blood test for prostate cancer (accuracy 94%, specificity 97%, sensitivity 86%)1, significantly boosting the accuracy of PSA alone. Crucially, the positive predictive value (PPV) of PSE is 93%, compared to just 25% for PSA. PSA's low PPV is one of the main arguments against using it as a population-wide screening test. About 25% of men with a raised PSA will go on to be diagnosed with prostate cancer. With the PSE, more than 9 out of every 10 men who receive a positive "high likelihood" PSE will go on to have a confirmatory biopsy1. This level of performance can reduce the total number of men who do not have prostate cancer being referred for unnecessary MRI scans and invasive biopsies2. These clinical results are supported by an accumulation of real-world evidence related to the clinical utility. Iain Ross, Executive Chairman of OBD, said: "Joining forces with a pioneering healthcare insurer like Bupa ensures that more men have access to an accurate diagnosis by using the EpiSwitch PSE test. Prostate Cancer is the most common cancer in men in the UK, and yet there is currently no nationwide screening programme due to limitations of current testing modalities. With its high accuracy and PPV, EpiSwitch PSE can be integrated into existing pathways to more precisely direct individuals toward further expensive and invasive diagnostics and treatments. We remain focused on forging strategic partnerships to build on this momentum and continue to drive value." |
Posted at 10/3/2025 14:29 by london07 www.bbc.com/news/artOBD sat on a goldmine! Serious questions being asked by leaders in the field with regards to PSA tests, OBD tests are superior and they are desperately needed. Prostate cancer is the fastest growing cancer worldwide. When this takes off, there will be no stopping. DYOR |
Posted at 03/3/2025 07:06 by bones698 Setting the bar very low with those options . One of my other companies set their target price at 5x the current share price and has had directors buying in the open market . Says a lot about how optimistic they are here . |
Posted at 28/2/2025 07:59 by kingston78 Zak Mir predicts that the share price will go up to 0.9 / 1 p level. |
Posted at 28/2/2025 07:07 by bones698 Those figures look even worse to me they are still burning through cash and don't have much left at all . Poorly managed and why the share price continues to fall and likely will again today . The tech is good but just another example of poor British management not keeping control and ensuring enough funding is in place to reach then end game of sales and income .I would say they have got the timing wrong by about 2 years here . Revenues not increasing anywhere near fast enough and losses increasing really bad. Several times he slides to more fund raises being required and streamlining the business with the help of shareholders . I suspect a lot more pain to come here with more rights issues at lower prices. Until they reach a point they can sustain the business or it goes under A shame the new guy didn't arrive much sooner he seems to have the right idea but unfortunately it may be to late . He will have to raise money the hard way and in these markets that will be painful . If he can do it though the longer term they might survive and do well but it's a long way off and a lot of pain before it gets there |
Posted at 20/2/2025 10:39 by kingston78 It is hard to comprehend that the share price was once at 100 p. It seems to me that the company has developed its products at a more advanced stage than ever before, and that it has secured adequate finance the new boss will take the company to a new height.This is one of my shares for 2025. Moreover, I will hold it for maybe two to three years to see 500% return. |
Posted at 17/2/2025 10:22 by anitabruzzese0 We’re thrilled to partner with Regina Maria, Romania’s largest private healthcare provider, serving 5 million patients.Regina Maria will integrate our EpiSwitch® PSE and CiRT tests into its oncology portfolio, expanding access to PSE and CiRT tests for physicians and patients across the country. Learn more: obdx.co/yke. #OBD #EpiSwitch #Oncology #PrecisionMedicine Latest post on X Massive news |
Posted at 14/2/2025 11:11 by edwardhimmers1977 Reddit Rumour @ OBDA leaked email on Reddit showing communication between OBDs CEO Ross, & the Romanian Health minister. The emails reveal 3 more contracts have been signed in Romania. It also confirms 2 new contracts in Spain have also been lined up.... The 3 Romanian contracts will be announced early next week. The news of how big the RNS regarding OBDs cancer test success, seems to have been overlooked by the markets. In the RNS the CEO states; ▪︎"Disc He gives that massive "nod" to the market in the 5th RNS!! RNS from 05/02 [3 main highlights] ▪︎ Results of multi-institutional clinical study published in peerx reviewed journal 'Cancers' confirms efficacy of Oxford BioDynamics' EpiSwitch® blood-based Colorectal No-Stool Test (NST) ▪︎ High accuracy of detection reported at 81% for early cancer stages and 82% for non-cancerous polyps ▪︎ Discussions are underway with potential partners to bring this potentially evolutionary test to clinical practice 12/02 RNS; "Oxford BioDynamics partners with Regina Maria to offer EpiSwitch clinical tests in Romania Regina Maria is Romania's largest private healthcare provider, serving 5 million patients OBD's EpiSwitch PSE and CiRT tests will be available to physicians and patients in Romania as part of Regina Maria's oncology portfolio" |
Posted at 24/12/2024 09:44 by bowerdean You would have thought that on Christmas Eve of all days, the directors of OBD might have said, instead of allotting themselves yet more shares in lieu of salary, “Having presided over a 90% share price fall since the last placing less than a year ago which was carried out using wildly over optimistic assumptions, the directors on this occasion are waiving their entitlement to shares in lieu of salary as a seasonal gesture to our long suffering shareholders”.Happy Christmas!! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
